de tuinman schreef op 18 augustus 2020 14:04:
[...]
Spannende tijden voor Arrowhead...
This means that our TRiM™ platform is now being studied in three different tissue types in human clinical trials. This is very exciting for us at Arrowhead and, we think, represents a significant step towards reaching the full therapeutic potential of RNA interference.”